{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T02:02:55Z","timestamp":1769047375709,"version":"3.49.0"},"reference-count":12,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Atopic dermatitis (AD) is a common chronic inflammatory skin condition. Currently, there is a lack of real-world evidence regarding the effectiveness of systemic therapies for moderate-to-severe AD. Abrocitinib is a novel Janus kinase 1 selective inhibitor licensed for AD in adults and adolescents requiring systemic treatment. The DREAM TO TREAT AD (D2T AD) study was set up to collect real-world data on abrocitinib and conventional systemic treatment use in moderate-to-severe AD. It aims to describe treatment patterns and effectiveness within a 3-year follow-up period in five registers: Ireland [Atopic Eczema Systemic Therapy Register (A-STAR) Ireland], Denmark (SCRATCH), Germany (TREATgermany), the Netherlands and Belgium (TREAT NL\/BE), and the UK (A-STAR UK).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The study protocol and methodology were developed collaboratively by academics of the participating registers with the study funder. The study follow-up timepoints and outcomes are based on an international Delphi exercise previously run by the TREAT Registry Taskforce. All five registers collect data in several domains, including patients\u2019 characteristics and treatment outcomes in patients receiving systemic treatment. Assignment to treatment was decided by the treating clinician. Data collected by the registers will be transformed into harmonized datasets and then to analytical datasets (ADS) to address research questions. Study objectives include describing patient baseline characteristics, in addition to clinician- (Eczema Area and Severity Index) and patient-reported outcomes [Patient-Reported Eczema Measure (POEM), Children\u2019s\/Dermatology Life Quality Index (C\/DLQI), Peak Pruritus Numeric Rate Scale (PP-NRS)] at baseline and follow-up, as well as treatment patterns while on abrocitinib and conventional systemic treatments. The ADS will be analysed using the novel DataSHIELD solution that enables centralized statistical analysis on decentralized data (i.e. without data leaving the register of origin). The DataSHIELD solution includes central analytic hubs (CAHs) and local data nodes (LDNs). CAH can remotely interrogate LDNs via an internet connection using analytical commands. Each LDN produces local statistical results that are sent back to the CAH, which can then combine the results from all LNDs without seeing any patient-level data.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Discussion<\/jats:title>\n                  <jats:p>D2T AD undertakes a novel federated data analysis approach across five registers in observational dermatology research and will provide crucial information on AD treatment outcomes for clinical decision-making, in addition to proving the feasibility of this type of scientific collaboration.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Protocol registration<\/jats:title>\n                  <jats:p>EMA RWD Catalogue (EU PAS no.: 108468; study ID: 199009; https:\/\/catalogues.ema.europa.eu\/node\/3894\/administrative-details).<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/skinhd\/vzaf020","type":"journal-article","created":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T15:59:07Z","timestamp":1745337547000},"page":"196-202","source":"Crossref","is-referenced-by-count":1,"title":["A pan-European register-based observational study of abrocitinib and conventional systemic therapies in moderate and severe atopic dermatitis: the DREAM TO TREAT AD study protocol"],"prefix":"10.1093","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5693-8194","authenticated-orcid":false,"given":"Elizaveta","family":"Gribaleva","sequence":"first","affiliation":[{"name":"Unit for Paediatric and Population-Based Dermatology Research, St John\u2019s Institute of Dermatology, King\u2019s College London , London ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niels Steen","family":"Krogh","sequence":"additional","affiliation":[{"name":"ZiteLab Aps , Copenhagen ,","place":["Denmark"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Prieto-Merino","sequence":"additional","affiliation":[{"name":"Unit for Paediatric and Population-Based Dermatology Research, St John\u2019s Institute of Dermatology, King\u2019s College London , London ,","place":["UK"]},{"name":"Faculty of Medicine, University of Alcal\u00e1 , Alcal\u00e1 de Henares ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bolaji","family":"Coker","sequence":"additional","affiliation":[{"name":"Research and Development Department, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust , London ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abaigeal","family":"Jackson","sequence":"additional","affiliation":[{"name":"Pfizer Healthcare Ireland , Dublin ,","place":["Ireland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmet","family":"Akkoc","sequence":"additional","affiliation":[{"name":"ZiteLab Aps , Copenhagen ,","place":["Denmark"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Birkner","sequence":"additional","affiliation":[{"name":"Center for Evidence-Based Healthcare, University Hospital Carle Gustav Carus Dresden and Medical Faculty, TU Dresden , Dresden, Sachsen ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erwin","family":"Bruninx","sequence":"additional","affiliation":[{"name":"Pfizer NV\/SA , Brussels ,","place":["Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Con","family":"Hennessy","sequence":"additional","affiliation":[{"name":"National and International Skin Registry Solutions CLG, Charles Institute of Dermatology, University College Dublin , Dublin ,","place":["Ireland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaitlyn","family":"Chan","sequence":"additional","affiliation":[{"name":"St John\u2019s Institute of Dermatology, Guy\u2019s and St Thomas\u2019 Hospitals NHS Trust , London ,","place":["UK"]},{"name":"School of Public Health, Brown University , Providence, RI ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lara","family":"Cutlar","sequence":"additional","affiliation":[{"name":"National and International Skin Registry Solutions CLG, Charles Institute of Dermatology, University College Dublin , Dublin ,","place":["Ireland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byron","family":"Farrell","sequence":"additional","affiliation":[{"name":"National and International Skin Registry Solutions CLG, Charles Institute of Dermatology, University College Dublin , Dublin ,","place":["Ireland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Godfrey","family":"Fletcher","sequence":"additional","affiliation":[{"name":"National and International Skin Registry Solutions CLG, Charles Institute of Dermatology, University College Dublin , Dublin ,","place":["Ireland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise","family":"Gerbens","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Amsterdam Public Health & Infection and Immunity, Amsterdam UMC, University of Amsterdam , Amsterdam ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne Grete","family":"Frostrup","sequence":"additional","affiliation":[{"name":"Pfizer ApS , Ballerup ,","place":["Denmark"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Henrohn","sequence":"additional","affiliation":[{"name":"Pfizer AB , Stockholm ,","place":["Sweden"]},{"name":"Department of Medical Sciences, Uppsala University , Uppsala ,","place":["Sweden"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ari\u00ebnna","family":"Hyseni","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Amsterdam Public Health & Infection and Immunity, Amsterdam UMC, University of Amsterdam , Amsterdam ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan D","family":"Irvine","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Trinity College , Dublin ,","place":["Ireland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rayka","family":"Malek","sequence":"additional","affiliation":[{"name":"Department of Life Sciences and Medicine, King\u2019s College London , London ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caitriona","family":"McCarthy","sequence":"additional","affiliation":[{"name":"Pfizer Healthcare Ireland , Dublin ,","place":["Ireland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3192-6135","authenticated-orcid":false,"given":"Ida","family":"Vittrup","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Copenhagen University Hospital , Copenhagen ,","place":["Denmark"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wouter","family":"Ouwerkerk","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Amsterdam Public Health & Infection and Immunity, Amsterdam UMC, University of Amsterdam , Amsterdam ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rowena","family":"Randall","sequence":"additional","affiliation":[{"name":"Pfizer Ltd , Tadworth ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phyllis I","family":"Spuls","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Amsterdam Public Health & Infection and Immunity, Amsterdam UMC, University of Amsterdam , Amsterdam ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4838-300X","authenticated-orcid":false,"given":"Simon Francis","family":"Thomsen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Copenhagen University Hospital , Copenhagen ,","place":["Denmark"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dmitri","family":"Wall","sequence":"additional","affiliation":[{"name":"Hair Restoration Blackrock , Dublin ,","place":["Ireland"]},{"name":"Charles Institute of Dermatology, School of Medicine, University College Dublin , Dublin ,","place":["Ireland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Weidinger","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, University Hospital Schleswig Holstein , Kiel, Schleswig-Holstein ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Werfel","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hannover Medical School , Hannover ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jochen","family":"Schmitt","sequence":"additional","affiliation":[{"name":"Center for Evidence-Based Healthcare, University Hospital Carle Gustav Carus Dresden and Medical Faculty, TU Dresden , Dresden, Sachsen ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4884-6286","authenticated-orcid":false,"given":"Carsten","family":"Flohr","sequence":"additional","affiliation":[{"name":"Unit for Paediatric and Population-Based Dermatology Research, St John\u2019s Institute of Dermatology, King\u2019s College London , London ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,4,22]]},"reference":[{"key":"2025062702353476500_vzaf020-B1","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.anai.2020.12.020","article-title":"Atopic dermatitis in the pediatric population: a cross-sectional, international epidemiologic study","volume":"126","author":"Silverberg","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2025062702353476500_vzaf020-B2","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.anai.2018.07.006","article-title":"Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study","volume":"121","author":"Silverberg","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2025062702353476500_vzaf020-B3","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jaad.2017.08.002","article-title":"The burden of atopic dermatitis in US adults: health care resource utilization data from the 2013 national health and wellness survey","volume":"78","author":"Eckert","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"2025062702353476500_vzaf020-B4","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/cea.14301","article-title":"Non-biologic systemic treatments for atopic dermatitis: current state of the art and future directions","volume":"53","author":"Paolino","year":"2023","journal-title":"Clin Exp Allergy"},{"key":"2025062702353476500_vzaf020-B5","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s40257-021-00618-3","article-title":"Integrated safety analysis of abrocitinib for the treatment of moderate-to-severe atopic dermatitis from the phase II and phase III clinical trial program","volume":"22","author":"Simpson","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"2025062702353476500_vzaf020-B6","doi-asserted-by":"crossref","first-page":"82","DOI":"10.4103\/2229-516X.157148","article-title":"Real world data: additional source for making clinical decisions","volume":"5","author":"Mahajan","year":"2015","journal-title":"Int J Appl Basic Med Res"},{"key":"2025062702353476500_vzaf020-B7","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/bjd.17715","article-title":"TREatment of ATopic eczema (TREAT) registry taskforce: consensus on how and when to measure the core dataset for atopic eczema treatment research registries","volume":"181","author":"Vermeulen","year":"2019","journal-title":"Br J Dermatol"},{"key":"2025062702353476500_vzaf020-B8","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/jdv.18566","article-title":"Mapping exercise and status update of eight established registries within the TREatment of ATopic eczema registry taskforce","volume":"37","author":"Bosma","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025062702353476500_vzaf020-B9","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/j.1365-2133.1994.tb08532.x","article-title":"The U.K. working party\u2019s diagnostic criteria for atopic dermatitis. III. Independent hospital validation","volume":"131","author":"Williams","year":"1994","journal-title":"Br J Dermatol"},{"key":"2025062702353476500_vzaf020-B10","author":"DataSHIELD: secure bioscience collaboration"},{"key":"2025062702353476500_vzaf020-B11","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1093\/ije\/dyu188","article-title":"DataSHIELD: taking the analysis to the data, not the data to the analysis","volume":"43","author":"Gaye","year":"2014","journal-title":"Int J Epidemiol"},{"key":"2025062702353476500_vzaf020-B12","author":"List of all DataSHIELD functions V6.1"}],"container-title":["Skin Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/skinhd\/article-pdf\/5\/3\/196\/62986968\/vzaf020.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/skinhd\/article-pdf\/5\/3\/196\/62986968\/vzaf020.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T06:35:41Z","timestamp":1751006141000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/skinhd\/article\/5\/3\/196\/8117747"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,22]]},"references-count":12,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,4,22]]},"published-print":{"date-parts":[[2025,6,27]]}},"URL":"https:\/\/doi.org\/10.1093\/skinhd\/vzaf020","relation":{},"ISSN":["2690-442X"],"issn-type":[{"value":"2690-442X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2025,4,22]]}}}